Karyopharm Therapeutics Inc.
karyopharm.comWhat Do They Do?
Sells XPOVIO, an oral cancer drug for people with multiple myeloma and diffuse large B-cell lymphoma, and develops medicines for patients with myelofibrosis and endometrial cancer.
10-K for FY2025, filed Feb 13, 2026We are a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development and…View ↗
In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one…View ↗
In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at…View ↗
For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (“DLBCL”), not otherwise specified, including…View ↗
Our primary focus is on marketing XPOVIO in its currently approved indications as well as developing and seeking regulatory approval of…View ↗
How Do They Make Money?
Product sales are the larger source of revenue: U.S. specialty pharmacies and distributors buy XPOVIO on delivery and generally pay within 30 to 68 days. Partners may pay license fees upfront, when options or milestones are reached, and as royalties on product sales.
10-K for FY2025, filed Feb 13, 2026We ship XPOVIO in the U.S. to specialty pharmacies and specialty distributors, collectively referred to as our customers, under a limited…View ↗
Each unit of XPOVIO that is ordered by our customers represents a distinct performance obligation that is completed when control of the…View ↗
Amounts are recorded as accounts receivable when our right to consideration is unconditional other than the passage of time. Accounts…View ↗
and participation on certain committees with the counterparty. Payments made by the customer may include non-refundable upfront fees…View ↗
-
10-K for FY2025, filed Feb 13, 2026
FY2025 revenue by product or service ↗
$146.1M
-
10-K for FY2025, filed Feb 13, 2026
$146.1M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product
Sold outright
10-K for FY2025, filed Feb 13, 2026 |
79%
FY2022: 77%
|
Product, FY2025
$114.9M Sources
|
Sold outright |
|
License and Other Revenue
Licensed
10-K for FY2025, filed Feb 13, 2026 |
21%
FY2022: 23%
|
License and Other Revenue, FY2025
$31.2M Sources
|
Licensed |
Who Are Their Customers?
In the U.S., specialty pharmacies and distributors buy XPOVIO directly from Karyopharm; pharmacies resell it to patients, while distributors sell it to healthcare entities. Outside the U.S., partners manage commercialization.
10-K for FY2025, filed Feb 13, 2026
Do Revenues Turn Into Profits?
No. It lost $196M in FY2025.
10-K for FY2025, filed Feb 13, 2026
−$90.7MView ↗
10-K for FY2025, filed Feb 13, 2026
−$196MView ↗
10-K for FY2025, filed Feb 13, 2026
−$75.4MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$67MView ↗
- ▲ +80% (Loss)
- vs −$37.3M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 13, 2026
Open tableView ↗
-
Aug 13, 2026
Reaffirmed full-year revenue guidance
The company kept its full-year total revenue range at $130 million to $150 million.
Sources
8-K, filed Aug 13, 2026
– Company Reaffirms Full-Year 2026 Total Revenue Guidance of $130 Million to $150 Million Including U.S. XPOVIO Net Product Revenue…View ↗
Shrinking. Revenue fell 30% in 4 years, from $209.8M in FY2021 to $146.1M in FY2025, about 9% a year.
A narrower development pipeline
The older report lists multiple myeloma, endometrial cancer, myelofibrosis and myelodysplastic neoplasms as priority programs, and describes plans for both selinexor and eltanexor. The latest report centers the clinical pipeline on selinexor in myelofibrosis, endometrial cancer and multiple myeloma, with further eltanexor work conditional on trial data and funding.
10-K for FY2022, filed Feb 17, 2023 10-K for FY2025, filed Feb 13, 2026
Who Do They Compete With?
Competes with Menarini, Stemline Therapeutics, and Shanghai Junshi Biosciences
10-K for FY2025, filed Feb 13, 2026There are numerous companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology…View ↗
Loading...
